Insmed (NASDAQ:INSM) Announces Quarterly Earnings Results

Key Points

• Insmed beat quarterly expectations with adjusted EPS of -$0.76 versus the -$0.90 consensus and revenue of $305.96 million, up 229.7% year over year.
• BRINSUPRI launch is outpacing expectations, with 44% sequential growth in Q1 and management reiterating at least $1 billion in 2026 revenue guidance for the drug.
• Pipeline progress remains a key catalyst, as ARIKAYCE’s ENCORE study showed statistically significant benefits and TPIP continues advancing in late-stage trials, while the company says it has about $1.2 billion in cash and expects cash-flow positivity in 2027.

Insmed (NASDAQ:INSM - Get Free Report) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.14, FiscalAI reports. Insmed had a negative net margin of 144.44% and a negative return on equity of 121.03%. The company had revenue of $305.96 million during the quarter, compared to analysts' expectations of $300.81 million. During the same period in the previous year, the company earned ($1.42) EPS. The business's revenue for the quarter was up 229.7% compared to the same quarter last year.

Here are the key takeaways from Insmed's conference call:

• BRINSUPRI launch is exceeding expectations with 44% sequential growth in Q1, >80% patient enrollment in the inLighten support program, ~90% specialty pharmacy approval rates, and management reiterates at least $1 billion in 2026 revenue guidance.
• Phase IIIb ENCORE for ARIKAYCE showed statistically significant improvement in patient‑reported respiratory symptoms and durable culture conversion, prompting plans to submit to US and Japanese regulators for a label expansion that could grow the addressable market from ~30k to >200k patients.
• TPIP is advancing through late‑stage development with the PALM‑PAH Phase III program open and PALM‑ILD enrolling across multiple countries, and OLE data (expected Q3) show some patients titrated to higher doses (up to 1,280 mcg), supporting dose feasibility for Phase III.
• Financially the company reported approximately $1.2 billion in cash and marketable securities and expects to achieve sustainable cash‑flow positivity in 2027 without raising additional capital, while Q1 gross‑to‑net metrics were within guided ranges.
• International rollout faces uncertainty from MFN/pricing dynamics—Insmed has paused broader Europe/U.K. commercialization due to potential price controls, which poses a material risk to international revenue expansion.

Insmed Price Performance

Shares of NASDAQ INSM traded down $3.83 during mid-day trading on Friday, hitting $101.17. 8,587,159 shares of the stock traded hands, compared to its average volume of 2,289,634. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.83 and a quick ratio of 3.54. Insmed has a twelve month low of $64.85 and a twelve month high of $212.75. The company has a market cap of $21.84 billion, a PE ratio of -17.60 and a beta of 0.89. The firm has a 50 day simple moving average of $145.87 and a two-hundred day simple moving average of $165.46.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on INSM. Roth Mkm reissued a "buy" rating and issued a $212.00 price objective on shares of Insmed in a research note on Friday, April 17th. Raymond James Financial assumed coverage on Insmed in a report on Friday, April 10th. They issued an "outperform" rating and a $200.00 target price on the stock. Bank of America boosted their price target on Insmed from $211.00 to $213.00 and gave the stock a "buy" rating in a report on Tuesday, March 24th. Truist Financial set a $205.00 price objective on Insmed in a research report on Monday, January 12th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Insmed in a research note on Tuesday, April 21st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $211.86.

Insiders Place Their Bets

In related news, CEO William Lewis sold 13,396 shares of the firm's stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $147.79, for a total value of $1,979,794.84. Following the completion of the transaction, the chief executive officer owned 301,185 shares in the company, valued at $44,512,131.15. This trade represents a 4.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Roger Adsett sold 88,060 shares of Insmed stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the sale, the chief operating officer owned 106,810 shares in the company, valued at approximately $17,584,130.30. This represents a 45.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 174,589 shares of company stock valued at $27,441,807 in the last 90 days. Corporate insiders own 2.10% of the company's stock.

Hedge Funds Weigh In On Insmed

A number of hedge funds have recently modified their holdings of the business. Darwin Global Management Ltd. increased its holdings in Insmed by 2.3% in the fourth quarter. Darwin Global Management Ltd. now owns 20,933,277 shares of the biopharmaceutical company's stock valued at $3,644,274,000 after purchasing an additional 475,832 shares during the period. State Street Corp grew its position in shares of Insmed by 30.6% in the 4th quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company's stock valued at $905,312,000 after buying an additional 1,217,390 shares during the last quarter. RTW Investments LP grew its position in shares of Insmed by 57.0% in the 4th quarter. RTW Investments LP now owns 4,842,879 shares of the biopharmaceutical company's stock valued at $842,855,000 after buying an additional 1,758,321 shares during the last quarter. Orbis Allan Gray Ltd increased its stake in shares of Insmed by 28.6% in the fourth quarter. Orbis Allan Gray Ltd now owns 4,179,957 shares of the biopharmaceutical company's stock valued at $727,480,000 after buying an additional 929,089 shares during the period. Finally, Invesco Ltd. boosted its holdings in Insmed by 36.1% in the fourth quarter. Invesco Ltd. now owns 2,726,857 shares of the biopharmaceutical company's stock valued at $474,582,000 after acquiring an additional 722,986 shares during the last quarter.

Insmed News Summary

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Insmed reported Q1 EPS of -$0.76, beating estimates, and revenue rose 229.7% year over year to $306 million. The company also reiterated major 2026 commercial goals, including at least $1 billion in BRINSUPRI revenue and $450 million to $470 million in ARIKAYCE revenue. Article: Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analysts at Royal Bank of Canada and Wells Fargo cut their price targets but kept bullish ratings, signaling they still see meaningful upside from current levels. RBC lowered its target to $205 from $220 and Wells Fargo cut to $160 from $177. Article: Benzinga report on RBC price target cut Article: The Fly report on Wells Fargo price target cut
• Neutral Sentiment: Insmed also highlighted progress on its pipeline and commercialization efforts, including positive ENCORE study results for ARIKAYCE and the start of the PALM-PAH study for TPIP. These updates support the long-term story, but they are less likely to move the stock immediately. Article: Insmed Q1 2026 Financial Results and Business Update
• Negative Sentiment: The stock is under pressure because Q1 sales came in below expectations and the company’s implied 2026 revenue guidance was below consensus, raising concerns that launch momentum may not be matching investor hopes. Article: Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%
• Negative Sentiment: Higher first-quarter expenses also weighed on sentiment, with market commentary pointing to increased costs as another reason investors sold the shares after earnings. Article: Insmed Shares Tumble Amid Higher 1Q Expenses

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.